{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T21:24:19Z","timestamp":1791149059531,"version":"4.1.0"},"reference-count":65,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2006,10,1]],"date-time":"2006-10-01T00:00:00Z","timestamp":1159660800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Lymphoma and Myeloma"],"published-print":{"date-parts":[[2006,10]]},"DOI":"10.3816\/clm.2006.s.002","type":"journal-article","created":{"date-parts":[[2008,9,12]],"date-time":"2008-09-12T01:03:13Z","timestamp":1221181393000},"page":"S7-S13","source":"Crossref","is-referenced-by-count":30,"special_numbering":"S1","title":["Treatment of Non-Hodgkin's Lymphoma: A Look over the Past Decade"],"prefix":"10.3816","volume":"7","author":[{"given":"Bertrand","family":"Coiffier","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.3816\/CLM.2006.s.002_bib1","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1002\/1097-0142(19820515)49:10<2112::AID-CNCR2820491024>3.0.CO;2-2","article-title":"National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas. Summary and description of a Working Formulation for Clinical Usage","volume":"49","author":"The Non-Hodgkin's Lymphoma Pathologic Classification Project","year":"1982","journal-title":"Cancer"},{"key":"10.3816\/CLM.2006.s.002_bib2","series-title":"Histopathology of Non-Hodgkin's Lymphomas","author":"Lennert","year":"1992"},{"key":"10.3816\/CLM.2006.s.002_bib3","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1093\/oxfordjournals.annonc.a058904","article-title":"European Lymphoma Task Force (ELTF): report of the workshop on mantle cell lymphoma (MCL)","volume":"5","author":"Zucca","year":"1994","journal-title":"Ann Oncol"},{"key":"10.3816\/CLM.2006.s.002_bib4","doi-asserted-by":"crossref","first-page":"2515","DOI":"10.1002\/1097-0142(19840601)53:11<2515::AID-CNCR2820531125>3.0.CO;2-C","article-title":"Extranodal malignant lymphoma arising from mucosa-associated lymphoid tissue","volume":"53","author":"Isaacson","year":"1984","journal-title":"Cancer"},{"key":"10.3816\/CLM.2006.s.002_bib5","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1182\/blood.V84.5.1361.1361","article-title":"A revised European-American classification of lymphoid neoplasms. A proposal from the International Lymphoma Study Group","volume":"84","author":"Harris","year":"1994","journal-title":"Blood"},{"key":"10.3816\/CLM.2006.s.002_bib6","series-title":"World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues","year":"2001"},{"key":"10.3816\/CLM.2006.s.002_bib7","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/35000501","article-title":"Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling","volume":"403","author":"Alizadeh","year":"2000","journal-title":"Nature"},{"key":"10.3816\/CLM.2006.s.002_bib8","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1056\/NEJMoa012914","article-title":"The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma","volume":"346","author":"Rosenwald","year":"2002","journal-title":"N Engl J Med"},{"key":"10.3816\/CLM.2006.s.002_bib9","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S1535-6108(03)00028-X","article-title":"The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma","volume":"3","author":"Rosenwald","year":"2003","journal-title":"Cancer Cell"},{"key":"10.3816\/CLM.2006.s.002_bib10","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1182\/blood-2003-05-1545","article-title":"Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray","volume":"103","author":"Hans","year":"2004","journal-title":"Blood"},{"key":"10.3816\/CLM.2006.s.002_bib11","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/0014-2964(79)90155-5","article-title":"Serum b2 microglobulin and its prognostic value in lymphomas","volume":"15","author":"Amlot","year":"1979","journal-title":"Eur J Cancer"},{"key":"10.3816\/CLM.2006.s.002_bib12","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1182\/blood.V54.4.928.928","article-title":"Serum lactic dehydrogenase as a prognostic tool for non-Hodgkin lymphomas","volume":"54","author":"Ferraris","year":"1979","journal-title":"Blood"},{"key":"10.3816\/CLM.2006.s.002_bib13","first-page":"1860","article-title":"Report of the Committee on Hodgkin's Disease Staging Classification","volume":"31","author":"Carbone","year":"1971","journal-title":"Cancer Res"},{"key":"10.3816\/CLM.2006.s.002_bib14","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1182\/blood.V74.2.558.558","article-title":"Prognosis of aggressive lymphoma: a study of five prognostic models with patients included in the LNH-84 regimen","volume":"74","author":"Coiffier","year":"1989","journal-title":"Blood"},{"key":"10.3816\/CLM.2006.s.002_bib15","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJM199309303291402","article-title":"A predictive model for aggressive non-Hodgkin's lymphoma","volume":"329","author":"The International Non-Hodgkin's Lymphoma Prognostic Factors Project","year":"1993","journal-title":"N Engl J Med"},{"key":"10.3816\/CLM.2006.s.002_bib16","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1200\/JCO.1994.12.7.1340","article-title":"Is the international prognostic index for aggressive lymphoma patients useful for follicular lymphoma patients?","volume":"12","author":"Bastion","year":"1994","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2006.s.002_bib17","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1093\/oxfordjournals.annonc.a059155","article-title":"Patterns of survival in mantle cell lymphoma","volume":"6","author":"Zucca","year":"1995","journal-title":"Ann Oncol"},{"key":"10.3816\/CLM.2006.s.002_bib18","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1182\/blood-2003-12-4434","article-title":"Follicular lymphoma international prognostic index","volume":"104","author":"Solal-Celigny","year":"2004","journal-title":"Blood"},{"key":"10.3816\/CLM.2006.s.002_bib19","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1023\/A:1008498705032","article-title":"Frequency and significance of anemia in non-Hodgkin's lymphoma patients","volume":"9","author":"Moullet","year":"1998","journal-title":"Ann Oncol"},{"key":"10.3816\/CLM.2006.s.002_bib20","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1093\/bioinformatics\/bti824","article-title":"Survival prediction of diffuse large-B-cell lymphoma based on both clinical and gene expression information","volume":"22","author":"Li","year":"2006","journal-title":"Bioinformatics"},{"key":"10.3816\/CLM.2006.s.002_bib21","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1200\/JCO.2005.02.4786","article-title":"Prognostic biomarkers in diffuse large B-cell lymphoma","volume":"24","author":"Lossos","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2006.s.002_bib22","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1002\/cncr.21586","article-title":"Biomarkers of potential prognostic significance in diffuse large B-cell lymphoma","volume":"106","author":"Wu","year":"2006","journal-title":"Cancer"},{"key":"10.3816\/CLM.2006.s.002_bib23","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1200\/JCO.2005.03.4264","article-title":"Bcl2 expression is a prognostic marker for the activated B-cell-like type of diffuse large B-cell lymphoma","volume":"24","author":"Iqbal","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2006.s.002_bib24","doi-asserted-by":"crossref","first-page":"4279","DOI":"10.1182\/blood-2002-11-3442","article-title":"Rituximab plus CHOP (R-CHOP) overcomes bcl-2-associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL)","volume":"101","author":"Mounier","year":"2003","journal-title":"Blood"},{"key":"10.3816\/CLM.2006.s.002_bib25","doi-asserted-by":"crossref","first-page":"4207","DOI":"10.1182\/blood-2005-10-4222","article-title":"Prognostic significance of Bcl-6 protein expression in DLBCL treated with CHOP or R-CHOP: a prospective correlative study","volume":"107","author":"Winter","year":"2006","journal-title":"Blood"},{"key":"10.3816\/CLM.2006.s.002_bib26","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1200\/JCO.1999.17.4.1244","article-title":"Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas","volume":"17","author":"Cheson","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2006.s.002_bib27","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1056\/NEJMra050276","article-title":"Positron-emission tomography and assessment of cancer therapy","volume":"354","author":"Juweid","year":"2006","journal-title":"N Engl J Med"},{"key":"10.3816\/CLM.2006.s.002_bib28","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1182\/blood-2005-01-0272","article-title":"[18F]fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in aggressive lymphoma: an early prognostic tool for predicting patient outcome","volume":"106","author":"Haioun","year":"2005","journal-title":"Blood"},{"key":"10.3816\/CLM.2006.s.002_bib29","first-page":"484","article-title":"First-line treatment of follicular lymphoma in the era of monoclonal antibodies","volume":"3","author":"Coiffier","year":"2005","journal-title":"Clin Adv Hematol Oncol"},{"key":"10.3816\/CLM.2006.s.002_bib30","doi-asserted-by":"crossref","first-page":"6387","DOI":"10.1200\/JCO.2005.05.015","article-title":"State-of-the-art therapeutics: diffuse large B-cell lymphoma","volume":"23","author":"Coiffier","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2006.s.002_bib31","doi-asserted-by":"crossref","first-page":"4117","DOI":"10.1200\/JCO.2005.09.131","article-title":"Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte","volume":"23","author":"Feugier","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2006.s.002_bib32","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1056\/NEJM199304083281404","article-title":"Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma","volume":"328","author":"Fisher","year":"1993","journal-title":"N Engl J Med"},{"key":"10.3816\/CLM.2006.s.002_bib33","doi-asserted-by":"crossref","first-page":"3025","DOI":"10.1200\/JCO.2000.18.16.3025","article-title":"Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin's lymphoma: final analysis of the prospective LNH87-2 protocol \u2013 a Groupe d'Etude des Lymphomes de l'Adulte Study","volume":"18","author":"Haioun","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2006.s.002_bib34","doi-asserted-by":"crossref","first-page":"4284","DOI":"10.1182\/blood-2003-02-0542","article-title":"Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin lymphoma","volume":"102","author":"Tilly","year":"2003","journal-title":"Blood"},{"key":"10.3816\/CLM.2006.s.002_bib35","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1182\/blood-2003-06-2095","article-title":"Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL","volume":"104","author":"Pfreundschuh","year":"2004","journal-title":"Blood"},{"key":"10.3816\/CLM.2006.s.002_bib36","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1056\/NEJMoa011795","article-title":"CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma","volume":"346","author":"Coiffier","year":"2002","journal-title":"N Engl J Med"},{"key":"10.3816\/CLM.2006.s.002_bib37","first-page":"40a","article-title":"Rituximab-CHOP versus CHOP with or without maintenance rituximab in patients 60 years of age or older with diffuse large B-cell lymphoma (DLBCL): an update","volume":"104","author":"Habermann","year":"2004","journal-title":"Blood"},{"key":"10.3816\/CLM.2006.s.002_bib38","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/S1470-2045(06)70664-7","article-title":"CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group","volume":"7","author":"Pfreundschuh","year":"2006","journal-title":"Lancet Oncol"},{"key":"10.3816\/CLM.2006.s.002_bib39","doi-asserted-by":"crossref","first-page":"9a","DOI":"10.1182\/blood.V106.11.13.13","article-title":"Six, not eight cycles of biweekly CHOP with rituximab (R-CHOP-14) is the preferred treatment for elderly patients with diffuse large B-cell lymphoma (DLBCL): results of the RICOVER-60 trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL)","volume":"106","author":"Pfreundschuh","year":"2005","journal-title":"Blood"},{"key":"10.3816\/CLM.2006.s.002_bib40","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1182\/blood-2004-08-3175","article-title":"CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma","volume":"105","author":"Marcus","year":"2005","journal-title":"Blood"},{"key":"10.3816\/CLM.2006.s.002_bib41","doi-asserted-by":"crossref","first-page":"3725","DOI":"10.1182\/blood-2005-01-0016","volume":"106","author":"Hiddemann","year":"2005","journal-title":"Blood"},{"key":"10.3816\/CLM.2006.s.002_bib42","doi-asserted-by":"crossref","first-page":"49a","DOI":"10.1182\/blood.V104.11.160.160","article-title":"Rituximab added to CHVP+IFN improves the outcome of follicular lymphoma patients: first analysis of the GELA-GOELAMS FL-2000 randomized trial","volume":"104","author":"Salles","year":"2004","journal-title":"Blood"},{"key":"10.3816\/CLM.2006.s.002_bib43","doi-asserted-by":"crossref","first-page":"169a","DOI":"10.1182\/blood.V104.11.584.584","article-title":"Results of a prospective randomized open label phase III study comparing rituximab plus mitoxantrone, chlorambucil, prednisolone chemotherapy (R-MCP) versus MCP alone in untreated advanced indolent non-Hodgkin's lymphoma and mantle cell lymphoma","volume":"104","author":"Herold","year":"2004","journal-title":"Blood"},{"key":"10.3816\/CLM.2006.s.002_bib44","first-page":"556","article-title":"Results of E1496: a phase III trial of CVP with or without maintenance with rituximab in advanced indolent lymphoma","volume":"23","author":"Hochster","year":"2004","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.3816\/CLM.2006.s.002_bib45","doi-asserted-by":"crossref","first-page":"41a","DOI":"10.1182\/blood.V104.11.130.130","article-title":"Yttrium-90 ibritumomab tiuxetan (Zevalin) for patients with relapsed\/refractory diffuse large B-cell lymphoma not appropriate for autologous stem cell transplantation: results of an open-label phase II trial","volume":"104","author":"Morschhauser","year":"2004","journal-title":"Blood"},{"key":"10.3816\/CLM.2006.s.002_bib46","first-page":"23","article-title":"Understanding the group of peripheral T-cell lymphomas, unspecified","volume":"4","author":"Zucca","year":"2005","journal-title":"Curr Hematol Rep"},{"key":"10.3816\/CLM.2006.s.002_bib47","doi-asserted-by":"crossref","first-page":"373","DOI":"10.3816\/CLM.2006.n.012","article-title":"The role of high-dose therapy in peripheral T-cell lymphomas","volume":"6","author":"Reimer","year":"2006","journal-title":"Clin Lymphoma Myeloma"},{"key":"10.3816\/CLM.2006.s.002_bib48","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1182\/blood-2005-03-1306","article-title":"T-cell non-Hodgkin lymphoma","volume":"107","author":"Rizvi","year":"2006","journal-title":"Blood"},{"key":"10.3816\/CLM.2006.s.002_bib49","doi-asserted-by":"crossref","first-page":"2826","DOI":"10.1200\/JCO.2004.12.032","article-title":"Prognostic factors in patients with aggressive non-Hodgkin's lymphoma treated by front-line autotransplantation after complete remission: a cohort study by the Groupe d'Etude des Lymphomes de l'Adulte","volume":"22","author":"Mounier","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2006.s.002_bib50","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1111\/joim.1997.242.s740.55","article-title":"Treatment of follicular follicle centre lymphomas \u2013 current status and future perspectives","volume":"242","author":"Hiddemann","year":"1997","journal-title":"J Intern Med"},{"key":"10.3816\/CLM.2006.s.002_bib51","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1200\/JCO.1998.16.8.2825","article-title":"Rituximab chimeric anti-Cd20 monoclonal antibody therapy for relapsed indolent lymphoma \u2013 half of patients respond to a four-dose treatment program","volume":"16","author":"McLaughlin","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2006.s.002_bib52","doi-asserted-by":"crossref","first-page":"107a","DOI":"10.1182\/blood.V106.11.353.353","article-title":"Chimeric anti-CD20 monoclonal antibody (rituximab; mabthera) in remission induction and maintenance treatment of relapsed\/resistant follicular non-Hodgkin's lymphoma: final analysis of a phase III randomized Intergroup clinical trial","volume":"106","author":"Van Oers","year":"2005","journal-title":"Blood"},{"key":"10.3816\/CLM.2006.s.002_bib53","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1200\/JCO.2004.10.086","article-title":"Stage I and II follicular non-Hodgkin's lymphoma: long-term follow-up of no initial therapy","volume":"22","author":"Advani","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2006.s.002_bib54","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10238-006-0087-6","article-title":"Radioimmunotherapy of B-cell lymphoma with radiolabelled anti-CD20 monoclonal antibodies","volume":"6","author":"Dillman","year":"2006","journal-title":"Clin Exp Med"},{"key":"10.3816\/CLM.2006.s.002_bib55","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1056\/NEJMoa041511","article-title":"131I-tositumomab therapy as initial treatment for follicular lymphoma","volume":"352","author":"Kaminski","year":"2005","journal-title":"N Engl J Med"},{"key":"10.3816\/CLM.2006.s.002_bib56","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1182\/blood-2003-01-0287","article-title":"A phase 2 trial of CHOP chemotherapy followed by tositumomab\/iodine I 131 tositumomab for previously untreated follicular non-Hodgkin lymphoma: Southwest Oncology Group protocol S9911","volume":"102","author":"Press","year":"2003","journal-title":"Blood"},{"key":"10.3816\/CLM.2006.s.002_bib57","doi-asserted-by":"crossref","first-page":"6409","DOI":"10.1200\/JCO.2005.55.017","article-title":"Current treatment approaches for mantle-cell lymphoma","volume":"23","author":"Witzig","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2006.s.002_bib58","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1002\/cncr.21313","article-title":"Chemotherapy with rituximab followed by high-dose therapy and autologous stem cell transplantation in patients with mantle cell lymphoma","volume":"104","author":"Thieblemont","year":"2005","journal-title":"Cancer"},{"key":"10.3816\/CLM.2006.s.002_bib59","first-page":"11","article-title":"Mantle cell lymphoma: from pathology and molecular pathogenesis to new therapeutic perspectives","volume":"91","author":"Salaverria","year":"2006","journal-title":"Haematologica"},{"key":"10.3816\/CLM.2006.s.002_bib60","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1002\/ajh.20137","article-title":"Prognostic factors influencing survival in patients with B-cell small lymphocytic lymphoma","volume":"77","author":"Nola","year":"2004","journal-title":"Am J Hematol"},{"key":"10.3816\/CLM.2006.s.002_bib61","doi-asserted-by":"crossref","first-page":"3034","DOI":"10.1182\/blood-2005-09-3679","article-title":"Infection-associated lymphomas derived from marginal zone B cells: a model of antigen-driven lymphoproliferation","volume":"107","author":"Suarez","year":"2006","journal-title":"Blood"},{"key":"10.3816\/CLM.2006.s.002_bib62","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1200\/JCO.2005.08.128","article-title":"Clinical activity of rituximab in gastric marginal zone non-Hodgkin's lymphoma resistant to or not eligible for anti-Helicobacter pylori therapy","volume":"23","author":"Martinelli","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2006.s.002_bib63","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1111\/j.1365-2559.2005.02309.x","article-title":"A clinicopathological study of nodal marginal zone B-cell lymphoma. A report on 21 cases","volume":"48","author":"Traverse-Glehen","year":"2006","journal-title":"Histopathology"},{"key":"10.3816\/CLM.2006.s.002_bib64","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/S1470-2045(03)00981-1","article-title":"Splenic marginal-zone lymphoma: a distinct clinical and pathological entity","volume":"4","author":"Thieblemont","year":"2003","journal-title":"Lancet Oncol"},{"key":"10.3816\/CLM.2006.s.002_bib65","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s11864-006-0014-9","article-title":"Management of marginal zone lymphomas","volume":"7","author":"Thieblemont","year":"2006","journal-title":"Curr Treat Options Oncol"}],"container-title":["Clinical Lymphoma and Myeloma"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1557919011703341?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1557919011703341?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,5,8]],"date-time":"2020-05-08T06:42:40Z","timestamp":1588920160000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1557919011703341"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,10]]},"references-count":65,"alternative-id":["S1557919011703341"],"URL":"https:\/\/doi.org\/10.3816\/clm.2006.s.002","relation":{},"ISSN":["1557-9190"],"issn-type":[{"value":"1557-9190","type":"print"}],"subject":[],"published":{"date-parts":[[2006,10]]}}}